Crossmark

586 Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.0586

Published Online: 2023-11-02

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Sarkar, Sandipto

Khan, Sahrish

Eads, Jennifer Rachel

Sharaiha, Reem

Carr-Locke, David

Chang, Lillian

Ginsberg, Gregory

DiCicco, Lisa

Garcia-Marcano, Luis

Hissong, Erika

Betel, Doron

Shah, Manish
License Information

License valid from 2023-10-21